Aeterna Zentaris Inc. (AEZS)

Aeterna Zentaris Inc. (AEZS) Fake Vaccine Press Release | Make Headlines for More Offerings
Sir Charles A. Henriques and I ( all in Zosano Pharma (ZSAN) https://twitter.com/CharlesAHenriq1
Zosano Pharma is actively seeking partnerships that utilize our proprietary transdermal microneedle patch technology. Zosano’s delivery technology has the capability to provide a room temperature stable, transdermal product to support a wide-spread deployment of a therapeutic solution.

PARTNERSHIP OPPORTUNITIES: PRODUCT, PIPELINE & PLATFORM

Zosano Product: Qtrypta for migraine and cluster headache
Commercialization, co-promotion / marketing partnership opportunities

Zosano Pipeline: Once-weekly parathyroid hormone for osteoporosis (ZP-PTH) in post-menopausal women
Phase 1 clinical development through commercialization partnership opportunities

Partner Product: Life-cycle management opportunities
Extensive experience with 505(b)(2) regulatory pathway for patent-life extension or competitive repositioning

Partner Program: Immunology / immuno-oncology research, discovery / co-development partnership opportunitie
Cancer vaccines and Immune activation / reactivation / overriding immunological tolerance

Partner Program: Prophylactic vaccines platform partnership opportunities
Pediatric and high-value adult vaccine co-development partnerships

AEZS diluted shares in 6 months, from26 million to 117 million share.

Many people are in ZSAN - Join us - take a loss - ZSAN will double soon.

Aeterna Zentaris Inc. (AEZS) What Does the Significant 410% Diluted Share Price Reveal?

When a corporation releases financial information, there are a few different variations used when reporting total earnings. These variations are: total dollar amounts, earnings as a percent of total revenue, earnings per share (EPS) and diluted EPS.

The last item, diluted EPS, means that earnings are reported on a hypothetical amount of outstanding shares, and is calculated by dividing the net income for a firm during a given reporting period by the total amount of shares outstanding plus all shares authorized for issuance. Examples of shares that can be authorized at a future date include those that result from call options and convertible bonds. This type of earnings analysis is very helpful when analyzing a firm's financial information and stock price.

The rationale behind such an analysis is to evaluate the effect that issuing all of the authorized stock at once would have on the company's underlying stock price. Because the number of shares outstanding increases, the value of all per-share figures reported will fall, and analyzing a firm on this basis would provide the investor with a better sense on the "true" value of a firm on a per-share basis.

Due diligence, Morgan's target price 25 cents.

Aeterna Zentaris Inc. (AEZS) Board of Director wish to thank all investors
holding 117 million AEZA shares a safe and healthy Covid -19 free year.
There will be no covid pill, perhaps from another company. Buy low sell high.
They now have enough money until reverse spilt is needed for Nasdaq rules.

Vaccine Global Pharma Investor and Marketer Switches to ZSAN
Sir Charles A. Henriques
Zosano history - Published: Jul 18, 2014 -Johnson & Johnson Spinout Zosano Pharma, Inc. Sets Terms For $70 Million IPO

Zosano Pharma, a biotech developing a transdermal delivery system to treat osteoporosis, announced terms for its IPO on Wednesday. The Fremont, CA-based company plans to raise $70 million by offering 6.4 million shares at a price range of $10 to $12. At the midpoint of the proposed range, it would command a fully diluted market value of $139 million.

Zosano Pharma, which was spun out of Johnson & Johnson ( JNJ ) in 2006 and booked $3 million in license fee revenue for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol ZSAN. Wedbush PacGrow, Ladenburg Thalmann and Roth Capital are the joint bookrunners on the deal. No pricing date was disclosed.

Vaccines: COVID-19 Partnering Opportunities. ( note copied from various sources and following Sir CAH )

Coated microneedles that deliver directly to epidermal/dermal skin layers which may lead to an improved response and potential for dose sparing therapies. One package, one dose. Room temperature stable, unit dose vaccine, delivered to the patient's door for at-home dosing.

With the ability to coat proteins, peptides, monoclonal antibodies, and vaccines, Zosano is eager to rise to the challenge of responding to the COVID crisis by collaborating with vaccine developers to provide the first microneedle vaccine for at home application. The technology is aimed at transforming vaccine dosing paradigms:

The company's lead clinical asset, Qtrypta*™ (zolmitriptan intracutaneous microneedle system), for the acute treatment of migraine with or without aura in adult patients, is currently under review by FDA.

Disclosure, I am not a ZSAN investor. Will be, buying Monday for as low as possible.

follow the Pharma gentleman on twitter as well.

Aeterna Zentaris Inc. (AEZS) tanking and glad we're out.
My dad and I following Sir Charles A. Henriques https://twitter.com/CharlesAHenriq1
Zosano Pharma Corporation (ZSAN)

We, like the intracutaneous microneedle system.

The system is a single-entity combination product, which comprises a reusable applicator and a microneedle array containing patch, for intracutaneous drug delivery allowing rapid absorption into the bloodstream. The microneedle array patch is applied to the skin using a ready to use and reusable handheld applicator.

Each microneedle array patch is individually packaged and stored at room temperature.

How it work.

An array of close to two thousand drug-coated titanium microneedles is mounted on the skin-facing surface of a backing that resembles an adhesive bandage. The length of each individual microneedle is about 3 times the width of a human hair.

When the microneedle patch is applied, the microneedles penetrate the outermost layer of the epidermis (stratum corneum). The shallow depth of penetration limits the likelihood of stimulating sensory nerve endings and causing pain. Interstitial fluid in the skin reconstitutes the drug and makes it available for rapid absorption into the bloodstream.

Rapid Systemic Delivery without the covid Needle and the advantages of intracutaneous delivery

There are instances where a drug cannot or should not be administered orally. For example, some drugs have poor oral bioavailability. In other cases, patients may not be able to tolerate an orally administered drug. In addition, intestinal absorption following oral delivery can be slow, delaying the beneficial effects of a drug.

Intracutaneous delivery allows systemic drug delivery without the use of a hypodermic needle. In clinical studies, less than 10% of patients reported any pain at the application site. Pharmacokinetic analysis demonstrated ~ 3-times faster absorption of zolmitriptan using our system compared with orally administered zolmitriptan.

Vaccines: COVID-19 Partnering Opportunities

With the ability to coat proteins, peptides, monoclonal antibodies, and vaccines, Zosano is eager to rise to the challenge of responding to the COVID crisis by collaborating with vaccine developers to provide the first microneedle vaccine for at home application.

The technology is aimed at transforming vaccine dosing paradigms:

Ideal Delivery

Coated microneedles that deliver directly to epidermal/dermal skin layers which may lead to an improved response and potential for dose sparing therapies.

One package, one dose: Room temperature stable, unit dose vaccine, delivered to the patient's door for at-home dosing
Stable: Zosano formulations are stable at room temperature, deployment using standard mail delivery systems

Easy disposal: Once applied the user would dispose of the unit in standard trash receptacles

Safe: The device prevents the user from inadvertently touching the microneedles and potentially removing some of the therapeutic.

Intuitive: Each patch is a unit dose, mitigating the need for a weight-adjusted calculation of dose, and preventing overdose or incorrect administration.

Proof of Concept: Successfully formulated and dosed >30 compounds of which 6 have advanced to clinical trials –including a Phase 1 trivalent vaccine.

Phase 1 clinical data for influenza vaccine showed that the microneedle coated tri-valent flu vaccine was comparable in immune response to the commercial IM injection.
Extensive clinical applications: Over 40,000 patch applications with no incidences of infection.


Notice: my aezs posts were deleted

Vaccines: COVID-19 Partnering Opportunities - A Better Investment
Sir Charles A. Henriques https://twitter.com/CharlesAHenriq1
Ideal Delivery Coated microneedles that deliver directly to epidermal/dermal skin layers which may lead to an improved response and potential for dose sparing therapies. One package, one dose. Room temperature stable, unit dose vaccine, delivered to the patient's door for at-home dosing.

With the ability to coat proteins, peptides, monoclonal antibodies, and vaccines, Zosano is eager to rise to the challenge of responding to the COVID crisis by collaborating with vaccine developers to provide the first microneedle vaccine for at home application. The technology is aimed at transforming vaccine dosing paradigms:

The company's lead clinical asset, Qtrypta*™ (zolmitriptan intracutaneous microneedle system), for the acute treatment of migraine with or without aura in adult patients, is currently under review by FDA. We expect that Qtrypta will be available, if approved, in 2021.

Zosano Pharma Corporation (ZSAN - glad I follow Sir Charles - only $1.28 - buy ratings and big holders.

Aeterna Zentaris Inc. (AEZS) shares out last week 63 Million to NOW 116.26 Million Shares Outstanding
Stock dilution, also known as equity dilution, is the decrease in existing shareholders' ownership percentage of a company as a result of the company issuing new equity. New equity increases the total shares outstanding which has a dilutive effect on the ownership percentage of existing shareholders. This increase in the number of shares outstanding can result from a primary market offering (including an initial public offering), employees exercising stock options, or by issuance or conversion of convertible bonds, preferred shares or warrants into stock. This dilution can shift fundamental positions of the stock such as ownership percentage, voting control, earnings per share, and the value of individual shares.

Aeterna Zentaris Inc. (AEZS) Board of Directors Pay Bleed Company Dry
As the Director of Aeterna Zentaris, the total compensation of Gilles Gagnon at Aeterna Zentaris is $980,550. There are no executives at Aeterna Zentaris getting paid more.

Gilles Gagnon biography

Gilles R. Gagnon serves as Director of the Company. He is currently the President and Chief Executive Officer of Ceapro Inc. Prior to that, he was President and CEO of Aeterna Zentaris Inc. During the past 35 years, Mr. Gagnon has worked at several management levels within the field of health, especially in the hospital environment and pharmaceutical industry. Mr. Gagnon has participated in several international committees and strategic advisory boards. He served nine years on the board of directors of Canada’s Research Based Pharmaceutical Companies (Rx&D—now Innovative Medicine Canada) where he represented members from the biopharmaceutical sector and pioneered the Rx&D’s Canadian Biopartnering initiative. He is currently a member of the CEO Council of Innovative Medicine Canada. He is a certified corporate Director having completed the Directors Education Program at the Rotman School of Management at the University of Toronto and he has served on several boards of both private and publicly listed companies in the biopharmaceutical sector.

As the Director of Aeterna Zentaris, the total compensation of Gilles Gagnon at Aeterna Zentaris is $980,550. There are no executives at Aeterna Zentaris getting paid more.

Aeterna Zentaris Inc. (AEZS) SEC investigate for fraud and other questionable tactics
The legend oF fake promises, class - action lawsuits, low revenues and self serving executives.
QUEBEC CITY, July 20, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it has successfully reached a key milestone in the non-clinical development of its live recombinant prostate cancer vaccine candidate, AEZS-120, for oral administration. The program, partially funded through a grant from the German government, encompassed the full development of a GMP process, including GMP production and quality testing of a clinical batch, as well as a non-clinical safety and toxicology package, as previously agreed with regulatory authorities. Subject to a positive review by German regulatory authorities, the Company aims to start Phase I clinical development in 2012.

The principle of AEZS-120 is based on the recombinant expression and secretion of the prostate specific antigen (PSA) in the approved attenuated vaccine strain Salmonella typhi Ty21a using a proprietary technology. The technology allows for the expression and secretion of an antigen genetically coupled to the non-toxic B subunit of cholera toxin to enhance immunogenicity. In principle, this platform technology is suitable for any prophylactic or therapeutic vaccine indication by varying the antigen.

AEZS-120 has been developed through a research collaboration with the Department of Medical Radiation Biology and Cell Research, and the Department of Microbiology of the University of Würzburg, Germany. The collaboration was funded with a total of $890,000 for Aeterna Zentaris and $870,000 for the university partner by the German Ministry of Education and Research (BMBF) for a period of three years. As part of the collaboration, a melanoma vaccine based on the recombinant expression of a modified B-Raf protein has been generated.

Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, "We are very enthusiastic about the potential of AEZS-120 which represents the first off-the shelf oral tumor vaccine in development and offers a favorable cost profile compared to individualized tumor vaccines. We believe that this successful key non-clinical milestone for AEZS-120 validates our strategy of employing public grants for the early development of highly innovative therapies."

Joachim Fensterle, Ph.D., Director, Head of Vaccine Development at Aeterna Zentaris and spokesperson for the research consortium added, "We now plan to fully complete the non-clinical package and discuss the data with regulatory authorities. Following a positive outcome of these discussions, we aim to file a clinical trial application at the beginning of 2012."

More Questionable presses release

CHARLESTON, S.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has entered into an exclusive option agreement to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine.
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg.

History company - since 1990 was done nothing for investors and shareholders.

Aeterna Zentaris fantasy vaccines to fund high paid management crooks. Example.
QUEBEC CITY, July 20, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it has successfully reached a key milestone in the non-clinical development of its live recombinant prostate cancer vaccine candidate, AEZS-120, for oral administration. The program, partially funded through a grant from the German government, encompassed the full development of a GMP process, including GMP production and quality testing of a clinical batch, as well as a non-clinical safety and toxicology package, as previously agreed with regulatory authorities. Subject to a positive review by German regulatory authorities, the Company aims to start Phase I clinical development in 2012.

Aeterna Zentaris Successfully Reached a Key Milestone in the Non-Clinical Development of its Oral Prostate Cancer Vaccine Candidate, AEZS-120

The principle of AEZS-120 is based on the recombinant expression and secretion of the prostate specific antigen (PSA) in the approved attenuated vaccine strain Salmonella typhi Ty21a using a proprietary technology. The technology allows for the expression and secretion of an antigen genetically coupled to the non-toxic B subunit of cholera toxin to enhance immunogenicity. In principle, this platform technology is suitable for any prophylactic or therapeutic vaccine indication by varying the antigen.

AEZS-120 has been developed through a research collaboration with the Department of Medical Radiation Biology and Cell Research, and the Department of Microbiology of the University of Würzburg, Germany.

Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg

CHARLESTON, S.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has entered into an exclusive option agreement to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine.

Now stalling on any vaccine news because they have none, they said a decision by the. middle of year, June or July is baloney. The company.diluted shareholder value by 400% in 6 months with offerings. First, they braged
that about enough money to run till 2023, then offered another 29 million in stock.

The numbers 7 months ago they had 26 million shares, today 117 million share,

Revenue projection by any analyst none, past product revenue almost zero.

due diligence - this company will have some serious lawsuits soon.